JNJ

172.53

-0.47%↓

ABBV

198.21

+0.48%↑

AZN

74.77

+0.99%↑

NVS

118.8

+0.7%↑

ABT

130.06

-1.06%↓

JNJ

172.53

-0.47%↓

ABBV

198.21

+0.48%↑

AZN

74.77

+0.99%↑

NVS

118.8

+0.7%↑

ABT

130.06

-1.06%↓

JNJ

172.53

-0.47%↓

ABBV

198.21

+0.48%↑

AZN

74.77

+0.99%↑

NVS

118.8

+0.7%↑

ABT

130.06

-1.06%↓

JNJ

172.53

-0.47%↓

ABBV

198.21

+0.48%↑

AZN

74.77

+0.99%↑

NVS

118.8

+0.7%↑

ABT

130.06

-1.06%↓

JNJ

172.53

-0.47%↓

ABBV

198.21

+0.48%↑

AZN

74.77

+0.99%↑

NVS

118.8

+0.7%↑

ABT

130.06

-1.06%↓

Search

10X Genomics Inc (Class A)

Deschisă

SectorSănătate

12.54 0.72

Rezumat

Modificarea prețului

24h

Curent

Minim

12.07

Maxim

12.78

Indicatori cheie

By Trading Economics

Venit

15M

-34M

Vânzări

-10M

155M

Marjă de profit

-22.183

Angajați

1,306

EBITDA

-1.5M

-39M

Recomandări

By TipRanks

Recomandări

Cumpărare

Prognoză pe 12 luni

+21.24% upside

Dividende

By Dow Jones

Următoarele câștiguri

28 oct. 2025

Statistici piață

By TradingEconomics

Capitalizare de piață

624M

1.7B

Deschiderea anterioară

11.82

Închiderea anterioară

12.54

Sentimentul știrilor

By Acuity

34%

66%

95 / 374 Clasament în Healthcare

Scor tehnic

By Trading Central

Încredere

Bullish Evidence

10X Genomics Inc (Class A) Grafic

Performanțele din trecut nu reprezintă un indicator fiabil al rezultatelor viitoare.

Știri relevante

11 aug. 2025, 17:49 UTC

Principalele dinamici ale pieței

180 Life Sciences Stock Jumps on $156 Million Notes Sale

11 aug. 2025, 17:18 UTC

Principalele dinamici ale pieței

Tiziana Life Sciences Rises After FDA Approves IND for Foralumab Trial

11 aug. 2025, 16:25 UTC

Câștiguri

Correction to Constellation Software 2Q Revenue Rises, Profit Shrinks Article on Aug. 8

11 aug. 2025, 23:50 UTC

Market Talk

Nikkei May Rise as Yen Weakens -- Market Talk

11 aug. 2025, 23:42 UTC

Market Talk

Global Energy Roundup: Market Talk

11 aug. 2025, 23:42 UTC

Market Talk

Woodside's Share Price Implies Lofty Oil Price -- Market Talk

11 aug. 2025, 23:36 UTC

Market Talk

Gold Edges Higher on Likely Technical Recovery -- Market Talk

11 aug. 2025, 23:32 UTC

Market Talk

Argosy's New Bull Sees Sentiment Toward REITs Improving -- Market Talk

11 aug. 2025, 23:02 UTC

Market Talk

RBA Set to Lower OCR With New Forecasts in Focus -- Market Talk

11 aug. 2025, 20:50 UTC

Market Talk

Basic Materials Roundup: Market Talk

11 aug. 2025, 20:37 UTC

Câștiguri
Achiziții, Fuziuni, Preluări

Bakkt Holdings: Andy Main Will Step Dn as Co-CEO and Director, Effective Aug 11, and Akshay Naheta Will Assume Role of CEO >BKKT

11 aug. 2025, 20:37 UTC

Câștiguri
Achiziții, Fuziuni, Preluări

Bakkt Holdings 2Q Rev $577.9M >BKKT

11 aug. 2025, 20:37 UTC

Câștiguri
Achiziții, Fuziuni, Preluări

Bakkt Holdings: In Upcoming Qtr, Will Conduct Comprehensive Review of Cost Structure to Ensure We Are Optimized, Driving Synergies Across Business, and Accelerating Path to Profitability >BKKT

11 aug. 2025, 20:22 UTC

Câștiguri

Exodus Movement: Assets 2,058 Units of Bitcoin Valued at $220.5M, 2,729 Units of Ether Valued at $6.8M, $58.1M in Cash and Cash Equivalents, USD Coin, Treasury Bills as of June 30 >EXOD

11 aug. 2025, 20:22 UTC

Câștiguri

Exodus Movement: Monthly Active Users 1.5M at End 2Q, Unchanged From 1.5M as of June 30, 2024 >EXOD

11 aug. 2025, 20:22 UTC

Câștiguri

Exodus Movement: Processed Volume $1.38B in 2Q Dn 37% From 1Q, Bitcoin, Tether (TRX Network), Tether (ETH Network), USDC, SOL Top Assets Traded in 2Q >EXOD

11 aug. 2025, 20:22 UTC

Câștiguri

Exodus Movement: Digital Assets and Liquid Assets $291.2M >EXOD

11 aug. 2025, 20:22 UTC

Câștiguri

Exodus Movement 2Q Rev $25.8M >EXOD

11 aug. 2025, 20:14 UTC

Market Talk

Canada Dollar Faces Near-Term Weakness on Trade Row, September Rate-Cut Chatter -- Market Talk

11 aug. 2025, 19:12 UTC

Market Talk

Crude-Oil Futures Edge Up in Rangebound Trade -- Market Talk

11 aug. 2025, 18:56 UTC

Market Talk

U.S. Natural-Gas Futures Fall on Forecast Loss of Late August Heat -- Market Talk

11 aug. 2025, 18:31 UTC

Market Talk

Mining Halt Could Lift Lithium Prices in Near Term -- Market Talk

11 aug. 2025, 17:43 UTC

Market Talk

Freeport-McMoRan Can Push Up Prices, Profits With Copper Tariff Protection -- Market Talk

11 aug. 2025, 17:28 UTC

Market Talk

Crossborder Trade Tensions Accelerate Softness in Canada Rents -- Market Talk

11 aug. 2025, 17:16 UTC

Market Talk

Commodity Longs Fall to 11-Month Low -- Market Talk

11 aug. 2025, 16:42 UTC

Achiziții, Fuziuni, Preluări

Adobe Stock Gets a Downgrade. 'AI Is Eating Software,' Analyst Says. -- Barrons.com

11 aug. 2025, 16:27 UTC

Achiziții, Fuziuni, Preluări

BBVA Says Sabadell Offer Remains in Effect

11 aug. 2025, 16:26 UTC

Achiziții, Fuziuni, Preluări

BBVA Previously Said It Won't Withdraw Offer to Buy Sabadell

11 aug. 2025, 16:25 UTC

Achiziții, Fuziuni, Preluări

Banco de Sabadell Announced TSB Sale on July 1

11 aug. 2025, 16:25 UTC

Achiziții, Fuziuni, Preluări

Banco de Sabadell Shareholders Approved TSB Unit Sale on Aug 6

Comparație

Modificare preț

10X Genomics Inc (Class A) Așteptări

Obiectiv de preț

By TipRanks

21.24% sus

Prognoză pe 12 luni

Medie 14.9 USD  21.24%

Maxim 18 USD

Minim 13 USD

În baza a 11 analiști de pe Wall Street care oferă obiective de preț pe 12 luni pentru10X Genomics Inc (Class A) - Dist în ultimele 3 luni.

Consens privind evaluarea

By TipRanks

Cumpărare

11 ratings

4

Cumpărare

7

Păstrare

0

Vânzare

Scor tehnic

By Trading Central

8.32 / 8.63Suport & Rezistență

Termen scurt

Bullish Evidence

Termen mediu

Bullish Evidence

Termen lung

No Evidence

Sentiment

By Acuity

95 / 374 Clasament în Sănătate

Sentimentul știrilor

Evidențe de creștere

Volatilitate

Sub medie

Volumul știrilor (RCV)

Medie

Date financiare

Cheltuieli de vânzare și administrare

Cheltuieli de exploatare

Profit pre-impozitare

Vânzări

Costul vânzărilor

Profit brut din vânzări

Cheltuieli cu dobânzile pe datorie

EBITDA

Profit operațional

$

Despre 10X Genomics Inc (Class A)

10x Genomics, Inc., a life science technology company, develops and sells instruments, consumables, and software for analyzing biological systems in the America, Europe, the Middle East, Africa, China, and the Asia Pacific. The company provides chromium, chromium connect, and chromium controller instruments, microfluidic chips, slides, reagents, and other consumables products. Its single cell solutions runs on its chromium instruments, which include single cell gene expression for measuring gene activity and networks on a cell-by-cell basis; single cell gene expression flex; single cell immune profiling used to study the immune system; single cell Assay for Transposase Accessible Chromati (ATAC) solution to understand the epigenetic state; and single cell multiome ATAC + gene expression which enables simultaneous interrogation of both the RNA and chromatin accessibility, using ATAC in a single cell. The company also provides Visium platform which enables researchers to understand the spatial positions of biological analytes within tissues at high resolution; and Xenium platform for in situ analysis. It serves various academic, government, biopharmaceutical, biotechnology, and other institutions. The company was formerly known as 10X Technologies, Inc. and changed its name to 10x Genomics, Inc. in November 2014. 10x Genomics, Inc. was incorporated in 2012 and is headquartered in Pleasanton, California.